- Consider pharmaceutical firms claiming access to a national market for an innovative drug. Pricing is regulated by the national Health Technology Assessment (HTA) agency.
- Consider an initial situation where pricing negotiations between the firm and the HTA agency only go through a Cost-Effectiveness Analysis (CEA) submitted by the firm and assessed by the agency. What kind of information is provided by that CEA? What kind and level of uncertainty is acceptable for the HTA agency? How does it (and should) influence price negotiations?
- After that initial period, the HTA agency decides to bring Budget Impact Analysis (BIA) into the evaluation process. What kind of information is contained in the BIA provided by the firm? Is BIA a complement or a substitute for CEA? How does BIA affect the uncertainty surrounding the evaluation procedure? How and to what extent does its introduction change the negotiation process?
Do you need help with this assignment or any other? We got you! Place your order and leave the rest to our experts.